Moderna Net Debt vs Non Current Assets Total Analysis
MRNA Stock | USD 41.11 2.86 7.48% |
Moderna financial indicator trend analysis is infinitely more than just investigating Moderna recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moderna is a good investment. Please check the relationship between Moderna Net Debt and its Non Current Assets Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
Net Debt vs Non Current Assets Total
Net Debt vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moderna Net Debt account and Non Current Assets Total. At this time, the significance of the direction appears to have pay attention.
The correlation between Moderna's Net Debt and Non Current Assets Total is -0.75. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Moderna, assuming nothing else is changed. The correlation between historical values of Moderna's Net Debt and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Moderna are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Net Debt i.e., Moderna's Net Debt and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | -0.75 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Moderna's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 1.2 B, whereas Issuance Of Capital Stock is forecasted to decline to about 43.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 18M | 200M | 405M | 425.3M | Net Interest Income | 18M | 200M | 363M | 381.2M |
Moderna fundamental ratios Correlations
Click cells to compare fundamentals
Moderna Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Moderna fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.6B | 7.3B | 24.7B | 25.9B | 18.4B | 19.3B | |
Total Current Liabilities | 143.1M | 4.4B | 9.1B | 4.9B | 3.0B | 2.4B | |
Total Stockholder Equity | 1.2B | 2.6B | 14.1B | 19.1B | 13.9B | 14.5B | |
Other Liab | 139.1M | 179.3M | 691M | 808M | 929.2M | 975.7M | |
Net Tangible Assets | 1.2B | 2.6B | 14.1B | 19.1B | 22.0B | 23.1B | |
Retained Earnings | (1.5B) | (2.2B) | 10.0B | 18.3B | 13.6B | 14.3B | |
Accounts Payable | 7.1M | 18M | 302M | 487M | 520M | 546M | |
Cash | 235.9M | 2.6B | 6.8B | 3.2B | 2.9B | 1.8B | |
Net Receivables | 16.3M | 1.4B | 3.2B | 1.4B | 892M | 848.5M | |
Other Current Assets | 887.9M | 252M | 607M | 1.4B | 643M | 462.8M | |
Total Liab | 414.6M | 4.8B | 10.5B | 6.7B | 4.6B | 3.1B | |
Total Current Assets | 1.3B | 6.3B | 16.1B | 13.4B | 10.3B | 5.6B | |
Common Stock | 33K | 34K | 40K | (857M) | (771.3M) | (732.7M) | |
Other Current Liab | 5.1M | 4.3B | 1.5B | 2.2B | 1.8B | 1.2B | |
Common Stock Shares Outstanding | 330.8M | 381.3M | 431M | 416M | 382M | 346.5M | |
Short Long Term Debt Total | 132.4M | 207.3M | 916M | 1.2B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 287.9M | 387M | 1.4B | 2.1B | 2.7B | 2.8B | |
Current Deferred Revenue | 63.3M | 3.9B | 6.3B | 2.0B | 568M | 539.6M | |
Net Debt | (103.5M) | (2.6B) | (6.8B) | (3.2B) | (1.7B) | (1.7B) | |
Non Current Assets Total | 326.4M | 1.0B | 8.6B | 12.4B | 8.1B | 4.3B | |
Non Currrent Assets Other | (121.5M) | 13M | 46M | 946M | 523M | 549.2M | |
Other Assets | 12.7M | 742.0M | 7.4B | 1.9B | 2.2B | 1.6B | |
Cash And Short Term Investments | 1.3B | 4.6B | 10.7B | 9.9B | 8.6B | 5.3B | |
Short Term Investments | 867.1M | 2.0B | 3.9B | 6.7B | 5.7B | 3.0B | |
Liabilities And Stockholders Equity | 1.6B | 7.3B | 24.7B | 25.9B | 18.4B | 11.3B | |
Non Current Liabilities Total | 271.5M | 387M | 1.4B | 1.8B | 1.6B | 868.0M | |
Capital Surpluse | 2.7B | 4.8B | 4.2B | 1.2B | 1.3B | 2.4B | |
Capital Lease Obligations | 132.4M | 207.3M | 916M | 1.0B | 1.2B | 1.3B | |
Other Stockholder Equity | 2.7B | 4.8B | 4.2B | 1.2B | 371M | 352.5M | |
Long Term Investments | 160.0M | 638.8M | 6.8B | 8.3B | 4.7B | 2.9B | |
Accumulated Other Comprehensive Income | 1.8M | 3M | (24M) | (370M) | (123M) | (116.9M) | |
Non Current Liabilities Other | 138K | 386.6M | 1.4B | 135M | 256M | 299.3M | |
Short Term Debt | 67.7M | 30M | 1.1B | 244M | 88M | 83.6M | |
Property Plant Equipment | 287.9M | 387.1M | 1.4B | 2.1B | 2.5B | 2.6B | |
Net Invested Capital | 1.2B | 2.6B | 14.1B | 19.1B | 13.9B | 8.1B | |
Property Plant And Equipment Gross | 287.9M | 387.1M | 1.7B | 2.1B | 3.1B | 3.2B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (5.81) | Revenue Per Share 13.275 | Quarterly Revenue Growth 0.017 | Return On Assets (0.1) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.